0.75Open0.35Pre Close20 Volume66 Open Interest2.00Strike Price1.37KTurnover157.72%IV4.65%PremiumAug 16, 2024Expiry Date0.58Intrinsic Value100Multiplier19DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.8136Delta0.2867Gamma3.69Leverage Ratio-0.0068Theta0.0007Rho3.00Eff Leverage0.0016Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet